{"id":"metformin-glimepiride","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"10-20","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Weight gain"},{"rate":"<1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_fixedAt":"2026-03-30T14:11:43.549649","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion. Together, they address both insulin resistance and beta-cell dysfunction in type 2 diabetes through complementary mechanisms.","oneSentence":"This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:22.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(65)"],"trialDetails":[{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT03118713","phase":"PHASE4","title":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT06644404","phase":"PHASE1","title":"Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-10-26","conditions":"Healthy","enrollment":34},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT03907423","phase":"NA","title":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2019-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT05663736","phase":"PHASE4","title":"Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2020-01-01","conditions":"Ejection Fraction","enrollment":80},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":"Type 2 Diabetes, Cardiovascular Risk Factor","enrollment":26},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT05162690","phase":"PHASE2, PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":40},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT02609815","phase":"NA","title":"Initial Combination of Gemigliptin and Metformin on Microbiota Change","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11-01","conditions":"Diabetes","enrollment":70},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":954},{"nctId":"NCT01437813","phase":"PHASE1","title":"BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2011-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01437800","phase":"PHASE1","title":"BIOAVAILABILITY OF GLI/METXR (4/850 mg)","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2011-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00679237","phase":"NA","title":"Risk Reduction in Coronary Heart Disease","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2007-09","conditions":"Coronary Heart Disease","enrollment":1600},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":3118},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02564926","phase":"PHASE4","title":"Foxiga Korea Local Phase 4 Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-01-05","conditions":"Diabetes Mellitus, Type 2","enrollment":125},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT01863667","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-07-08","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT00427154","phase":"PHASE3","title":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":388},{"nctId":"NCT03585777","phase":"","title":"Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2018-10-11","conditions":"Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment","enrollment":90},{"nctId":"NCT02567994","phase":"PHASE3","title":"Tenelia Triple Combination Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-04","conditions":"Type 2 Diabetes Mellitus","enrollment":201},{"nctId":"NCT01561976","phase":"NA","title":"Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-30","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT02484209","phase":"PHASE3","title":"DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)","status":"WITHDRAWN","sponsor":"Diabetes Frail Ltd","startDate":"2016-02","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT02823808","phase":"PHASE4","title":"Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2017-07","conditions":"Diabetes","enrollment":96},{"nctId":"NCT02007278","phase":"PHASE4","title":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-03","conditions":"Type 2 Diabetes, Hypoglycemia","enrollment":40},{"nctId":"NCT01725672","phase":"PHASE1","title":"Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT00032487","phase":"PHASE3","title":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2000-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1791},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00701090","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":1035},{"nctId":"NCT00614120","phase":"PHASE3","title":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT00469586","phase":"PHASE3","title":"Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-04-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01233622","phase":"PHASE3","title":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT01517373","phase":"PHASE2","title":"Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":304},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT00331851","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":584},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT00133718","phase":"PHASE4","title":"A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2002-01","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00619697","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":260},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT01167881","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1549},{"nctId":"NCT01425580","phase":"PHASE2","title":"Liraglutide and Heart Failure in Type 2 Diabetes","status":"COMPLETED","sponsor":"Thomas Nystrom","startDate":"2012-01","conditions":"Congestive Heart Failure, Type 2 Diabetes Mellitus","enrollment":62},{"nctId":"NCT01481116","phase":"PHASE3","title":"Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2454},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT00449605","phase":"PHASE3","title":"A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Diabetes Mellitus, Type 2","enrollment":508},{"nctId":"NCT02142309","phase":"PHASE4","title":"Glycemic Durability After Metformin Failure","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":450}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"MYALGIA"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ARTERIOSCLEROSIS"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BLISTER"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"BLOOD PRESSURE SYSTOLIC INCREASED"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":65,"recentPublications":[{"date":"2026 Mar 11","pmid":"41900041","title":"Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.","journal":"Molecules (Basel, Switzerland)"},{"date":"2025 Aug","pmid":"41041193","title":"Reappraisal of cardiometabolic stress in type 2 diabetes mellitus patients receiving glimepiride versus insulin under bitherapy.","journal":"Journal of family medicine and primary care"},{"date":"2024 Sep 1","pmid":"39687954","title":"Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients.","journal":"Indian journal of pharmacology"},{"date":"2024","pmid":"38962295","title":"Effects of metformin on arterial elasticity and pro-inflammatory markers in black diabetes patients.","journal":"Health SA = SA Gesondheid"},{"date":"2024 Jun 21","pmid":"38907201","title":"Trends in commonly used and potentially inappropriate medications in older Korean patients with polypharmacy.","journal":"BMC geriatrics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rosiglitazone-metformin fixed dose combination"],"phase":"marketed","status":"active","brandName":"metformin + glimepiride","genericName":"metformin + glimepiride","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}